NOTTINGHAM, UK – 16 June, 2021 – Life Science Newswire – Leading Drug Discovery Contract Research Organisation Sygnature Discovery has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving the way for clinical trials.With over £1m of capital investment already committed, the new world-class facility and business unit will be operational in September 2021 and is being set…
Health, Safety and Biosafety Consultant, Dr Bishop Simon, will be presenting a free biosafety webinar in collaboration with the Institution of Occupational Safety and Health. This session offers insight into the controls used by safety professionals to protect our laboratory research scientist and the community around them, as they work to make the discoveries needed to advance the treatment of diseases. This session will be of interest to you if: a) you are curious about how this is achieved in general and during the COVID pandemic, b) if you've considered working in the sector as a…
Cambridge, UK, 14 June 2021: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has appointed Dr Christian Dillon as Vice President of Biology. In this new role, Dr Dillon will work across all the Company’s areas of interest, including oncology, targeted protein degradation, and neurodegeneration, leading PhoreMost’s efforts to progress the novel targets identified by its SITESEEKER® platform towards drug discovery.
Christian joins PhoreMost from Cancer Research UK’s Therapeutic Discovery Laboratories (CRUK-TDL…
The next round of the Biomedical Catalyst will launch on 7th June. £18 Million is available to support industry-led research and development projects that seek to provide solutions to Health and Care challenges.
The Biomedical Catalyst funding programme supports UK businesses to test and develop innovative technologies for health and care. The programme provides funding to help UK SMEs speed up the process of bringing new products to market and secure onward investment.
The Biomedical Catalyst was established in 2012 with the aim of delivering…
Air Products is pleased to announce that it has extended its agreement with One Nucleus for another two years. It means that One Nucleus members can benefit from preferential rates on liquid gases and associated equipment from Air Products until at least 2023.
As a preferred partner of One Nucleus, members have access to Air Products’ full range of liquid gases and associated equipment, including freezers, tanks and cryogenic shippers. Stephen Robinson, Life Science Product Manager at Air Products, commented that: “Through our partnership with One Nucleus we have the opportunity to work with…
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER
Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief Operating Officer.
Lindsey brings a wealth of deep expertise and experience from the life science industry, with roles covering strategy, marketing, project management and corporate development. Having completed a PhD in…
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR STERILE PRODUCTS TO DEVELOP A STABLE READY TO USE PRODUCT
Cambridge, UK, 7th June 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (“Par”).
Under this agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated, stable,…
Click here to view the June 2021 edition of eNews - an ON Helix preview.
Cambridge, UK: 08 June 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes bringing connections to expert advisers and business intelligence sources to enable members to create their corporate development plans from a position of knowledge. PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For nearly 30…
Uppsala, Sweden June 7th 2021, - LINK Medical, a full-service contract research organization (CRO) providing product development and post-marketing services for the pharmaceutical and medical device industries, has signed a contract to join forces with Insife, an expert consulting and technology service provider for safety and pharmacovigilance organizations.
This partnership combines extensive experience and know-how from LINK Medical with a robust, enabling technology from Insife, providing LINK Medical with a top-of-the line safety database and other powerful supporting modules.
A fully-…